Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.

Postoperative tissue fibrosis represents a major complication in orthopedics. Transforming growth factor beta 1 is a key molecule in the development of postoperative fibrosis. High concentrations of transforming growth factor beta 1 have also been implicated in various diseases. Agents that counteract the actions of transforming growth factor beta 1 have been investigated as potential antifibrotic medications and as adjunct treatment to platelet-rich plasma injections (increased amounts of transforming growth factor beta 1) to improve their effectiveness and/or safety profile. Losartan blocks transforming growth factor beta 1 action and has attracted special interest in orthopedic research that focuses on how to reduce the risk of postoperative fibrosis. [Orthopedics. 2018; 41(5):e591-e597.].

[1]  T. Ichim,et al.  Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis , 2017, Journal of Translational Medicine.

[2]  W. Chou,et al.  Short-term clinical results of intra-articular PRP injections for early osteoarthritis of the knee. , 2017, International journal of surgery.

[3]  Liyun Gao,et al.  Cdk5 is required for the neuroprotective effect of transforming growth factor-β1 against cerebral ischemia-reperfusion. , 2017, Biochemical and biophysical research communications.

[4]  H. Ouyang,et al.  Intratendon Delivery of Leukocyte-Poor Platelet-Rich Plasma Improves Healing Compared With Leukocyte-Rich Platelet-Rich Plasma in a Rabbit Achilles Tendinopathy Model , 2017, The American journal of sports medicine.

[5]  Suting Li,et al.  Therapeutic Effect and Mechanism of Electrical Stimulation in Female Stress Urinary Incontinence. , 2017, Urology.

[6]  W. Blot,et al.  High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study , 2016, BMC Nephrology.

[7]  Freddie H. Fu,et al.  The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries , 2016, The American journal of sports medicine.

[8]  S. Hurwitz,et al.  Customized platelet-rich plasma with transforming growth factor β1 neutralization antibody to reduce fibrosis in skeletal muscle. , 2016, Biomaterials.

[9]  Cecilia G. Sanchez,et al.  Regulation of transforming growth factor-beta1 (TGF-β1)-induced pro-fibrotic activities by circadian clock gene BMAL1 , 2016, Respiratory Research.

[10]  J. Oh,et al.  Comparison of the Cellular Composition and Cytokine-Release Kinetics of Various Platelet-Rich Plasma Preparations , 2015, The American journal of sports medicine.

[11]  J. Wang,et al.  The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells - implications of PRP application for the clinical treatment of tendon injuries , 2015, Stem Cell Research & Therapy.

[12]  B. Dawson,et al.  Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. , 2015, Molecular genetics and metabolism.

[13]  P. Hopkins.  TGFB1 regulation and novel therapies for osteoarthritis , 2015 .

[14]  M. Weir,et al.  Novel RAAS agonists and antagonists: clinical applications and controversies , 2015, Nature Reviews Endocrinology.

[15]  C. Clase,et al.  Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria , 2014, Annals of Internal Medicine.

[16]  K. Lyons,et al.  TGFβ signaling in cartilage development and maintenance. , 2014, Birth defects research. Part C, Embryo today : reviews.

[17]  H. Klobučar,et al.  Functional results and patient satisfaction after arthroscopic capsular release of idiopathic and post-traumatic stiff shoulder , 2014, International Orthopaedics.

[18]  R. O’Keefe,et al.  Deletion of the transforming growth factor β receptor type II gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice. , 2013, Arthritis and rheumatism.

[19]  Freddie H. Fu,et al.  The timing of administration of a clinically relevant dose of losartan influences the healing process after contusion induced muscle injury. , 2013, Journal of applied physiology.

[20]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[21]  G. Vanderstraeten,et al.  Treatment of Skeletal Muscle Injury: A Review , 2012, ISRN orthopedics.

[22]  A. Lubkowska,et al.  Growth factor content in PRP and their applicability in medicine. , 2012, Journal of biological regulators and homeostatic agents.

[23]  Freddie H. Fu,et al.  Biological approaches to improve skeletal muscle healing after injury and disease. , 2012, Birth defects research. Part C, Embryo today : reviews.

[24]  N. Frangogiannis,et al.  TGF-β signaling in fibrosis , 2011, Growth factors.

[25]  B. Fleming,et al.  Reduced platelet concentration does not harm PRP effectiveness for ACL repair in a porcine in vivo model , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[26]  Alaa M. Hegazy,et al.  Arthroscopic Arthrolysis for Arthrofibrosis of the Knee after Total Knee Replacement , 2011, HSS Journal ®.

[27]  C. Ward,et al.  Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in Sarcopenia , 2011, Science Translational Medicine.

[28]  J. Zielak,et al.  Platelet‐rich plasma (PRP) impairs the craniofacial bone repair associated with its elevated TGF‐β levels and modulates the co‐expression between collagen III and α‐smooth muscle actin , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[29]  F. Jamali,et al.  Renal adverse effects of nonsteroidal anti-inflammatory drugs , 2009, Expert opinion on drug safety.

[30]  Freddie H. Fu,et al.  Blocking VEGF as a potential approach to improve cartilage healing after osteoarthritis. , 2008, Journal of musculoskeletal & neuronal interactions.

[31]  E. Bradley,et al.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. , 2008, Experimental cell research.

[32]  G. Sharp,et al.  TGF-β Promotes Thyroid Epithelial Cell Hyperplasia and Fibrosis in IFN-γ-Deficient NOD.H-2h4 Mice1 , 2008, The Journal of Immunology.

[33]  Yong Li,et al.  Angiotensin II Receptor Blockade Administered after Injury Improves Muscle Regeneration and Decreases Fibrosis in Normal Skeletal Muscle , 2008, The American journal of sports medicine.

[34]  Juan Li,et al.  Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[36]  M. Frigerio,et al.  Drugs for left ventricular remodeling in heart failure. , 2005, The American journal of cardiology.

[37]  Freddie H. Fu,et al.  The Effect of Relaxin Treatment on Skeletal Muscle Injuries , 2005, The American journal of sports medicine.

[38]  J. Huard,et al.  The Use of Relaxin Improves Healing in Injured Muscle , 2005, Annals of the New York Academy of Sciences.

[39]  Yong Li,et al.  The Use of Suramin, an Antifibrotic Agent, to Improve Muscle Recovery after Strain Injury , 2005, The American journal of sports medicine.

[40]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  T. Hansen,et al.  Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. , 2004, Bone.

[42]  T. MacDonald,et al.  Review of aldosterone- and angiotensin II-induced target organ damage and prevention. , 2004, Cardiovascular research.

[43]  S. Abe,et al.  Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist , 2003, Thorax.

[44]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[45]  Yong Li,et al.  Muscle injuries and repair: current trends in research. , 2002, The Journal of bone and joint surgery. American volume.

[46]  R. Derynck,et al.  TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. , 2001, Genes & development.

[47]  T. Sampson.  Complications of Hip Arthroscopy , 2001 .

[48]  Johnny Huard,et al.  The Use of an Antifibrosis Agent to Improve Muscle Recovery after Laceration * , 2001, The American journal of sports medicine.

[49]  R Treuting,et al.  Minimally invasive orthopedic surgery: arthroscopy. , 2000, The Ochsner journal.

[50]  F. Reinholt,et al.  The long‐term effect of a short course of transforming growth factor‐β1 on rat articular cartilage , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[51]  N. Nakamura,et al.  Temporal and spatial expression of transforming growth factor‐β in the healing patellar ligament of the rat , 1997, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[52]  D. Averill,et al.  Mechanisms of angiotensin-induced hypotension and bradycardia in the medial solitary tract nucleus. , 1994, The American journal of physiology.

[53]  J. Massagué,et al.  Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites , 1994, The Journal of cell biology.

[54]  R. Derynck,et al.  Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. , 1993, Science.

[55]  F. Fawthrop.  Inflammation: Basic Principles and Clinical Correlates , 1993 .

[56]  R. Derynck,et al.  Extracellular matrix regulates expression of the TGF-beta 1 gene , 1993, The Journal of cell biology.

[57]  Freddie H. Fu,et al.  The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. , 2013, Osteoarthritis and cartilage.